帕利哌酮缓释片与利培酮治疗老年精神分裂症患者的疗效与安全性

Efficacy and Safety of Paliperidone Extended-Release Tablets and Risperdal in Treatment of Elder Schizophrenia Patients

目的该研究主要对比帕利哌酮缓释片和利培酮治疗老年精神分裂症的疗效和安全性。方法该项研究对于年龄≥65岁,PANSS≥70分的精神分裂症患者随机分配进入帕利哌酮缓释片组和利培酮口服液组,并分别用两种药物进行治疗,人际和社会功能量表(PSP)来评价在急性期治疗患者的疗效。结果显示其平行轮廓检验F=0.523,P=0.451,说明两组患者PANSS总评分的总体轮廓平行。结论采用帕利哌酮缓释片与利培酮治疗老年精神分裂症的疗效相当,无明显不良反应。

Objective To study the efficacy and safety of paliperidone extended-release tablets and risperdal in treatment of elder schizophrenia patients. Methods This study for age ≥65 years, PANSS≥70 points schizophrenic patients were randomly assigned into the group of paliperidone extended release tablets and oral risperidone group, and were treated with both drugs, interpersonal and Social Functioning Scale（PSP） to evaluate the efficacy of the patients in the acute phase of treatment. Results The outline of its parallel test F=0.523,P=0.451, illustrating the overall outline of the two groups of parallel PANSS total score. Conclusion The use of paliperidone extended release tablets and risperidone in the treatment of schizophrenia efficacy quite elderly, no significant adverse reactions.